Soleus Capital Management L.P. Boosts Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Soleus Capital Management L.P. lifted its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,494,420 shares of the company's stock after purchasing an additional 150,755 shares during the period. Jasper Therapeutics comprises about 2.0% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 16th largest position. Soleus Capital Management L.P. owned 9.96% of Jasper Therapeutics worth $31,951,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Wells Fargo & Company MN grew its holdings in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares during the last quarter. EntryPoint Capital LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $223,000. Tema Etfs LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter worth about $266,000. Barclays PLC grew its holdings in shares of Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company's stock worth $304,000 after purchasing an additional 12,308 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Jasper Therapeutics by 239.8% in the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock worth $308,000 after purchasing an additional 11,567 shares during the last quarter. 79.85% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JSPR shares. UBS Group cut their price target on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Finally, Oppenheimer cut their price target on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $62.22.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock traded down $0.10 during midday trading on Friday, hitting $4.77. 90,973 shares of the company's stock were exchanged, compared to its average volume of 292,623. Jasper Therapeutics, Inc. has a 12 month low of $3.13 and a 12 month high of $26.84. The firm has a 50-day moving average of $4.55 and a two-hundred day moving average of $10.42. The company has a market cap of $71.65 million, a PE ratio of -1.01 and a beta of 2.74.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24). As a group, equities analysts expect that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.